<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613544</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-120</org_study_id>
    <nct_id>NCT04613544</nct_id>
  </id_info>
  <brief_title>Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker</brief_title>
  <official_title>A Prospective, Open Label, Multi-Center, Pilot Study to Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiokol Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiokol Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Voice Assist Arrhythmia Monitoring (VAAM) is an application running on smartphones and/or&#xD;
      landline phones that performs vocal tests for the monitoring of abnormalities in the heart&#xD;
      rhythm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following ICF signature and process and eligibility confirmation, subject will have a&#xD;
      training session to assure correct application use. The subjects will be asked to pronounce&#xD;
      few vowels 3 times a day to be evaluated by the application analysis algorithm at the patient&#xD;
      natural environment.&#xD;
&#xD;
      At the same time, a single lead ECG system will be recorded synchronously ECG for reference&#xD;
      with the use of dedicated recording device&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>6 weeks</time_frame>
    <description>related Adverse device effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usability</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of User Experience and User Interface</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness</measure>
    <time_frame>6 wweeks</time_frame>
    <description>application specificity and sensitivity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation</arm_group_label>
    <description>Atrial fibrillation diagnosed patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Voice Assist Arrhythmia Monitoring (VAAM)</intervention_name>
    <description>application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.</description>
    <arm_group_label>Atrial Fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Atrial Fibrillation Diagnosed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female and male at age of â‰¥18 years and above.&#xD;
&#xD;
          2. All AF types Or Medical history of Cryptogenic stroke.&#xD;
&#xD;
          3. Ability and willingness to sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with implanted cardiac defibrillators or pacemakers neurostimulators and/or&#xD;
             body worn medical devices such as insulin pumps.&#xD;
&#xD;
          2. Subjects diagnosed with any heart arrhythmias other than A-Fib, except for PVC.&#xD;
&#xD;
          3. Patient who underwent cardioversion or ablation in the last year and is in stable&#xD;
             sinus rhythm.&#xD;
&#xD;
          4. Women who are pregnant or breastfeeding (women of child-bearing potential must provide&#xD;
             a declaration stating that they are not pregnant)&#xD;
&#xD;
          5. Tremor or Parkinson's disease&#xD;
&#xD;
          6. Current hoarseness&#xD;
&#xD;
          7. Barriers for communication and lack of capability to execute the handlings required&#xD;
             for this study.&#xD;
&#xD;
          8. Subjects who are currently enrolled in another clinical investigation. Parallel&#xD;
             Enrollment to a non-interventional study is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Omelchenko, MD</last_name>
      <phone>972-9-7472573</phone>
      <email>alexom36@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Golovchiner, MD</last_name>
      <phone>9723-9377107</phone>
      <email>gregoryg@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

